



Polyclonal Spread of Fosfomycin Resistance among Carbapenemase-Producing Members of the *Enterobacterales* in the Czech Republic

 V. Mattioni Marchetti,^{a,b} L. Kraftova,^{a,b} M. Finianos,^{a,b} T. Sourenian,^{a,b}  J. Hrabak,^{a,b} I. Bitar^{a,b}

^aDepartment of Microbiology, Faculty of Medicine, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic

^bBiomedical Center, Faculty of Medicine, Charles University, Pilsen, Czech Republic

ABSTRACT Fosfomycin (FOS) has been recently reintroduced into clinical practice, but its effectiveness against multidrug-resistant (MDR) *Enterobacterales* is reduced due to the emergence of FOS resistance. The copresence of carbapenemases and FOS resistance could drastically limit antibiotic treatment. The aims of this study were (i) to investigate fosfomycin susceptibility profiles among carbapenem-resistant *Enterobacterales* (CRE) in the Czech Republic, (ii) to characterize the genetic environment of *fosA* genes among the collection, and (iii) to evaluate the presence of amino acid mutations in proteins involved in FOS resistance mechanisms. During the period from December 2018 to February 2022, 293 CRE isolates were collected from different hospitals in the Czech Republic. FOS MICs were assessed by the agar dilution method (ADM), FosA and FosC2 production was detected by the sodium phosphonoformate (PPF) test, and the presence of *fosA*-like genes was confirmed by PCR. Whole-genome sequencing was conducted with an Illumina NovaSeq 6000 system on selected strains, and the effect of point mutations in the FOS pathway was predicted using PROVEAN. Of these strains, 29% showed low susceptibility to fosfomycin (MIC, ≥ 16 $\mu\text{g/mL}$) by ADM. An NDM-producing *Escherichia coli* sequence type 648 (ST648) strain harbored a *fosA10* gene on an IncK plasmid, while a VIM-producing *Citrobacter freundii* ST673 strain harbored a new *fosA7* variant, designated *fosA7.9*. Analysis of mutations in the FOS pathway revealed several deleterious mutations occurring in GlpT, UhpT, UhpC, CyaA, and GlpR. Results regarding single substitutions in amino acid sequences highlighted a relationship between ST and specific mutations and an enhanced predisposition for certain STs to develop resistance. This study highlights the occurrence of several FOS resistance mechanisms in different clones spreading in the Czech Republic.

IMPORTANCE Antimicrobial resistance (AMR) currently represents a concern for human health, and the reintroduction of antibiotics such as fosfomycin into clinical practice can provide further option in treatment of multidrug-resistant (MDR) bacterial infections. However, there is a global increase of fosfomycin-resistant bacteria, reducing its effectiveness. Considering this increase, it is crucial to monitor the spread of fosfomycin resistance in MDR bacteria in clinical settings and to investigate the resistance mechanism at the molecular level. Our study reports a large variety of fosfomycin resistance mechanisms among carbapenemase-producing *Enterobacterales* (CRE) in the Czech Republic. Our study summarizes the main achievements of our research on the use of molecular technologies, such as next-generation sequencing (NGS), to describe the heterogeneous mechanisms that reduce fosfomycin effectiveness in CRE. The results suggest that a program for widespread monitoring of fosfomycin resistance and epidemiology fosfomycin-resistant organisms can aid timely implementation of countermeasures to maintain the effectiveness of fosfomycin.

Editor Rafael Vignoli, Instituto de Higiene

Copyright © 2023 Mattioni Marchetti et al.

This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to V. Mattioni Marchetti,

vittoria.mattionimarche01@univipavia.it.

The authors declare no conflict of interest.

Received 23 January 2023

Accepted 31 March 2023

Published 26 April 2023

KEYWORDS *Enterobacteriales*, carbapenemase producers, fosfomycin, drug-resistance bacteria, WGS

Fosfomycin (FOS) is a phosphoric acid derivate, active against both Gram-negative and Gram-positive bacteria. It was discovered in 1969, and it gained renewed clinical interest in the last 20 years as a good candidate in the treatment of multidrug-resistant (MDR) bacterial infections (1). According to the Food and Drug Administration (FDA) and the European Medicine Agency (EMA), FOS is approved for oral use in uncomplicated lower urinary tract infections (UTI) and for systemic use in complicated UTI and bacterial meningitis (https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050717s005lbl.pdf). FOS binds to UDP-*N*-acetylglucosamine enolpyruvyl transferase (MurA), which interferes with the early stages of peptidoglycan production (2). FOS uptake inside bacterial cell depends on two transport systems: the glycerol-3-phosphate transporter (GlpT) and the glucose-6-phosphate transporter (UhpT). The expression of GlpT and UhpT is glycerol-3 (G3P) and glucose-6-phosphate (G6P) dependent and requires the presence of cyclic AMP (cAMP). Moreover, UhpT expression is further controlled by the UhpABC system (2). Inactivation of UhpABC impairs expression levels of UhpT and affects FOS uptake into the cytosol (3–8).

The levels of cAMP are directly related to the adenylate cyclase CyaA and to the phosphotransferase PtsI. The occurrence of mutations in both CyaA and PtsI alters cAMP intracellular levels and, consequently, FOS uptake (9) (Fig. 1).

Several mutations can take place at different steps of the above-mentioned pathway, affecting FOS uptake and leading to different extents of FOS resistance (2, 10, 11). Alteration of GlpT/UhpT activity and mutations in MurA are considered the primary FOS resistance mechanism, followed by impairment in UhpA, CyaA, and PtsI activity (9) (Fig. 1).

In recent years, a great deal of attention has been given to FOS-modifying enzymes, such as FosA. FosA is a metalloenzyme that catalyzes the opening of the FOS epoxide ring, leading to its inactivation (12). As of December 2022, 10 *fosA* variants have been reported on both chromosomes and plasmids in members of the *Enterobacteriales*. *fosA*-like genes are chromosomally distributed in *Providencia* spp. and *Serratia marcescens* (*fosA*), in *Enterobacter* spp. (*fosA2*), in *Salmonella* species (*fosA7*), and in *Klebsiella pneumoniae* (*fosA5* and *fosA6*) (12). In contrast, plasmid-mediated dissemination is recognized for *fosA3*, *fosA4*, *fosA8*, *fosA9*, and *fosA10* among *Escherichia coli* and *K. pneumoniae* strains (13–16). Epidemiologically, FosA3 is the most widespread variant, with endemic cases reported from both veterinary and clinical settings in China (13, 17–19); FosA7 is predominantly found in isolates from veterinary settings (20, 21). FosA5 has been reported from clinical settings in China (22, 23) and from food in India (24), while FosA10 has been detected only in chicken meat from China (16). Few cases from food and clinical samples reported the occurrence of FosA8 (25, 26), while only one clinical case involving FosA9 has been described from a clinical case in the Netherlands (27). The co-occurrence of FosA enzymes and extended-spectrum β -lactamases (ESBLs), including carbapenemases, in *Enterobacteriales* has been already reported in the literature, limiting the use of FOS in clinical practice (28, 29). Co-occurrence of FosA enzymes and carbapenemases has been mainly described for *K. pneumoniae* (17, 28, 30), with sporadic occurrences in *E. coli* (31–33) and two reports of occurrences in *Citrobacter freundii* (34).

Escherichia coli is an intestinal commensal of warmed-blood animals that has the ability to cause diseases such as extraintestinal infections (13). *Citrobacter* spp. are low-risk pathogens but, as reported in the literature, can act as a silent reservoir for relevant resistance genes, especially *C. freundii* (35). The occurrence of FosA enzymes has been documented worldwide, but large epidemiological investigations of their occurrence in *E. coli* and in *Citrobacter* spp. are lacking, especially among European countries. The Czech Republic has an active and broad surveillance program for carbapenem-resistant *Enterobacteriales* (CRE) among clinical settings (36, 37), but no epidemiological investigation of FOS resistance




FIG 1 FOS uptake and pathway inside the bacterial cell. (Step 1) GlpT transports G3P and fosfomycin inside the bacterial cell. GlpT expression is mediated by G3P. (Step 2) Inside the cytoplasm, FOS binds to MurA and interferes with the formation of UDP-GlcNAc enolpyruvate, the first stage of peptidoglycan biosynthesis. (Step 3) GlpR acts as a repressor for GlpT expression. In the cytoplasm, G3P attaches to GlpR, blocking its binding to *glpT* promoter. (Step 4) PtsI transfers a P group from PEP (2-phosphoenolpyruvate) to PtsH. The P group is then transferred to CRR by PtsH. CRR-P and PtsI activate CyaA (4). CyaA is an adenylate cyclase that converts the ATP to cAMP. cAMP binds to the CRP, and the cAMP-CRP complex promotes expression of both GlpT and UhpT (5). (Step 5) cAMP-CRP complex promotes GlpT expression, binding to *glpT* promoter. The activity of the cAMP-cAMP receptor protein (CRP) complex is enhanced by FNR (6). (Step 6) UhpT promotes the entry of G6P and FOS into the cell. The presence of G6P enhances the expression levels of UhpT. (Step 7) The UhpABC system promotes the expression of UhpT. UhpC binds extracellular G6P, and through UhpB, a phosphate group is transferred to UhpA (UhpA-P). (Step 8) UhpA-P is the activate form of UhpA and, together with cAMP-CRP complex, starts UhpT transcription, binding to the *uhpT* promoter. (Step 9) PtsG promotes the entry of glucose into the cell (7). (Step 10) GlpQ is a periplasmic glycerophosphodiester phosphodiesterase that converts periplasmic glycerophosphodiester to G3P (8).

among these strains has been conducted recently. Moreover, as reported in previous studies, the Czech Republic has an increasing number of cases of disease caused by carbapenemase-producing *E. coli* and *C. freundii*, and the occurrence of fosfomycin resistance mechanisms in such isolates represents a concerning public health issue (35–37).

The aim of our study was to characterize the epidemiology of FOS resistance in the Czech Republic clinical setting in *E. coli* and *Citrobacter* carbapenemase producers. Moreover, an additional aim was to characterize the resistance mechanisms of FOS resistance through the detection of *fosA*-like genes and through the detection of specific point mutations in the associated transporters and regulators involved in uptake.

RESULTS

All 293 *Enterobacteriales* strains were carbapenemase producers: 132/293 produced NDM-type enzymes (111 [84%] *E. coli* and 21 [16%] *Citrobacter* isolates), 106/293 produced OXA-48-type (76 [72%] *E. coli* and 30 [28%] *Citrobacter* isolates), 50/293 produced KPC-type enzymes (33 [66%] *E. coli* and 17 [34%] *Citrobacter* isolates), and 5/293 produced VIM-type enzymes (3 [60%] *E. coli* and 2 [40%] *Citrobacter* isolates). The agar dilution method (ADM) showed that 71% (208/293) of the isolates retained susceptibility to FOS (MIC \leq 8 $\mu\text{g}/\text{mL}$) and the remaining 29% (85/293) showed low-susceptibility/resistance profiles. In detail, 41 of 85 (38 [93%] *E. coli* and 3 [7%] *C. freundii* isolates) had FOS MICs of 16 $\mu\text{g}/\text{mL}$, 18 of 85 (16 [89%] *E. coli* and 2 [11%] *C. freundii* isolates) had FOS MICs of 32 $\mu\text{g}/\text{mL}$, and 26 of 85 (16 [62%] *E. coli* and 10 [38%] *C. freundii*

isolates) had FOS MICs of ≥ 64 $\mu\text{g/mL}$. The sodium phosphonoformate (PPF) test was performed on strains with FOS MICs of ≥ 64 $\mu\text{g/mL}$, and only two of 26 FOS-resistant strains were FosA/FosC2 enzyme producers.

PCR investigations of the two strains detected *fosA10* in an NDM-producing strain of *E. coli* (ECO49406) and a *fosA7* gene in a VIM-producing *C. freundii* strain (CFR50714). *fosA10* was successfully transferred by conjugation, while attempts to transfer *fosA7* through conjugation and transformation failed.

***fosA10* in NDM-producing *E. coli*.** Whole-genome sequencing (WGS) revealed that ECO49406 belonged to sequence type 648 (ST648)/unknown sequence type (Oxford scheme/Pasteur scheme), serotype O102:H6, and the CH type FumC4/FimH27 (fimbrial adhesion gene *fimH* with allele 27 and fumarate hydratase class II gene *fumC* with allele 4). The resistome of ECO49406 consisted of β -lactam (*bla*_{NDM-5}), fosfomycin (*fosA10*), aminoglycoside (*aadA2* and *aadA5*), folate pathway antagonist (*dfrA12*, *dfrA17*, and *sul-1*), tetracycline [*tet(B)*], macrolide [*mph(A)*], and quaternary ammonium compound (*qacE*) resistance genes. Moreover, ECO49406 carried a multireplicon IncFIB/FII and an IncK plasmid. Additionally, the virulome consisted of *air*, *chuA*, *eilA*, *fyuA*, *gad*, *irp2*, *iss*, *kpsE*, *kpsMII_K5*, *lpfA*, *ompT*, *terC*, *traT*, and *yfcV* (Table 1).

Based on short-read data and conjugation experiments, *fosA10* was located on the IncK plasmid. *fosA10* was in a genomic cassette of 3,835 bp consisting of *excA*-DEAD box-*fosA10*-*lysR*-IS10R. The BLAST results showed that the cassette shared 100% query and identity with the *fosA10* cassette of the IncB/O/K/Z plasmid p542093_1 (accession no. CP091410.1) and 65% query and 100% identity with the *fosA10* cassette reported in an IncFII plasmid (pHNPK9-Fos; accession no. MT074415.1) (16) collected from veterinary *E. coli* isolates in China. pHNPK9-*fosA10* cassette (4,328 bp) differed only by (i) containing two copies of IS10 flanking *fosA10* and the DEAD box and (ii) lacking *excA* (Fig. 2).

***fosA7.9* in VIM-producing *C. freundii*.** Based on WGS data, *C. freundii* CFR50714 belonged to ST673 and harbored antibiotic resistance genes for β -lactam (*bla*_{VIM-1} and *bla*_{CMY-78}), fosfomycin (*fosA7*), aminoglycoside [*aadA1*, *aac(6')-Ib3*, and *aac(6')-Ib-cr*], folate pathway antagonist (*dfrA14*, *sul-1*, and *sul-2*), quinolone (*qnrS1*), macrolide [*mph(A)*] and quaternary ammonium compound (*qacE*). The *fosA7* gene was 423 bp in length and encoded a 140-amino-acid protein. The *fosA7* gene shared highest identity (93.38% identity and 100% query) with the *fosA7.4* variant (accession no. NG_067230.1) and encoded a protein showing 95% identity with FosA7.4 (accession no. WP_023216493.1) and 93.4% with FosA7.5 (Fig. 3 and 4). *fosA7.9* was inserted into a 12,065-bp cassette consisting of the following genes: the HNH endonuclease gene, *fosA7.9*, *fic*, the type II endonuclease restriction gene, the methyltransferase gene, and the HNH endonuclease gene. The BLAST results revealed that the cassette showed similarity with several strains collected worldwide: 100% query and 99.98% identity with the NDM+FosA7.9 coproducer *C. freundii* L75, collected in China in 2018 from a urine sample (accession no. CP047307) (38), and with the CMY-2+FosA7.9 coproducer *C. freundii* RHBSTW-00135, collected in 2017 from wastewater influent in the United Kingdom (accession no. CP056827) (39). Additionally, the *fosA7.9* cassette shared 81% query and 94.34% identity with a chromosome cassette of *Citrobacter koseri* SCAID-URN1-2019 (accession no. CP052059.1) collected in Kazakhstan from a urine sample (40), and with *C. koseri* BAA-895, collected in Maryland from an infant with meningitis (accession no. CP000822.1). Interestingly, the cassette in *C. koseri* lacked the flanking HNH and *fosA7.9* but had an identical *fic* cassette (*fic*-type II endonuclease restriction-methyltransferase) in the same orientation (Fig. 5). The *in silico* analysis and the failed attempts at conjugation suggested a chromosomal location for *fosA7.9*. Sequence data from strain CFR50714, *C. freundii* L75 (CP047307), and *C. freundii* RHBSTW-00135 (CP056827) were used to investigate their genomic relatedness to global isolates, to construct a single nucleotide polymorphism (SNP)-based phylogenetic tree. The three aforementioned sequences were compared against 103 genomes found in the NCBI database (Fig. 5). Strain CFR50714 clustered with *C. freundii* RHBSTW-00135 (ST396) and *C. freundii* L75 (ST396), forming a clade (Fig. 6).

TABLE 1 WGS data for FOS-susceptible and -resistant strains studied^a

| Strain | Origin | Location | Species | FOS MIC (µg/mL) and category | FosA variant | Serotype | FumC/FimH | Plasmid | ST (Oxford/Pasteur) | Virulence genes | Other resistance genes | Accession no. |
|-----------------------|-------------|----------------|--------------------|------------------------------|--------------|----------|-----------|------------------------------------|---------------------|--|--|-------------------|
| ECO49406 | Rectal swab | Prague | <i>E. coli</i> | >128, R | 10 | O_H_ | 4/27 | IncK, IncFIB (pB171), IncFII | ST648/unknown | <i>air</i> , <i>chuA</i> , <i>eiaA</i> , <i>fyuA</i> , <i>gad</i> , <i>irp2</i> , <i>iss</i> , <i>kpsE</i> , <i>kpsMII</i> , <i>KS</i> , <i>lpfA</i> , <i>ompT</i> , <i>terC</i> , <i>traT</i> , <i>yfcV</i> | <i>aadA2</i> , <i>aadA3</i> , <i>sul-1</i> , <i>dfra12</i> , <i>dfra17</i> , <i>tet(B)</i> , <i>mph(A)</i> , <i>bla_{NDM-5}</i> , <i>qacE</i> | JAPEQT0000000000 |
| ECO52246 | Urine | Nymburk | <i>E. coli</i> | >128, R | ND | O_H_ | 40/30 | IncFII(K), IncR | ST131/43 | <i>chuA</i> , <i>fyuA</i> , <i>gad</i> , <i>iha</i> , <i>irp2</i> , <i>iss</i> , <i>kpsE</i> , <i>ompT</i> , <i>sat</i> , <i>stfA</i> , <i>terC</i> , <i>traT</i> , <i>usp</i> , <i>yfcV</i> | <i>aph(6)-Id</i> , <i>aac(6)-Ib3</i> , <i>aph(3)-Ib</i> , <i>aac(6)-Ib-cr</i> , <i>tet(A)</i> , <i>mph(A)</i> , <i>qnrB1</i> , <i>sul-1</i> , <i>sul-2</i> , <i>dfra14</i> , <i>ARR-3</i> , <i>bla_{OXA-1}</i> , <i>bla_{TEM-1b}</i> , <i>bla_{RFC-3}</i> , <i>qacE</i> , <i>catB3</i> | JAPJVB0000000000 |
| ECO52259 | Rectal swab | Jičín | <i>E. coli</i> | >128, R | ND | O_H_ | 40/30 | IncFII(K), IncR | ST131/43 | <i>chuA</i> , <i>fyuA</i> , <i>gad</i> , <i>iha</i> , <i>irp2</i> , <i>iss</i> , <i>kpsE</i> , <i>ompT</i> , <i>sat</i> , <i>stfA</i> , <i>terC</i> , <i>traT</i> , <i>usp</i> , <i>yfcV</i> | <i>aph(6)-Id</i> , <i>aac(6)-Ib3</i> , <i>aph(3)-Ib</i> , <i>aac(6)-Ib-cr</i> , <i>tet(A)</i> , <i>mph(A)</i> , <i>qnrB1</i> , <i>sul-1</i> , <i>sul-2</i> , <i>dfra14</i> , <i>ARR-3</i> , <i>bla_{OXA-1}</i> , <i>bla_{TEM-1b}</i> , <i>bla_{RFC-3}</i> , <i>qacE</i> , <i>catB3</i> | JAPJVC0000000000 |
| ECO52250 ^b | Urine | Jičín | <i>E. coli</i> | 4, S | ND | O_H_ | 43/197 | IncR | 2558/unknown | <i>chuA</i> , <i>clbB</i> , <i>cnf1</i> , <i>focC</i> , <i>fyuA</i> , <i>gad</i> , <i>hra</i> , <i>ibea</i> , <i>iroN</i> , <i>irp2</i> , <i>iss</i> , <i>kpsE</i> , <i>kpsMII</i> , <i>mchB</i> , <i>mchC</i> , <i>mchF</i> , <i>mcmA</i> , <i>ompT</i> , <i>papA</i> , <i>FT3</i> , <i>papC</i> , <i>pic</i> , <i>stfA</i> , <i>stfA</i> , <i>terC</i> , <i>usp</i> , <i>vat</i> , <i>yfcV</i> | <i>aac(6)-Ib3</i> , <i>aac(6)-Ib-cr</i> , <i>mph(A)</i> , <i>sul-1</i> , <i>ARR-3</i> , <i>bla_{RFC-3}</i> , <i>bla_{OXA-1}</i> , <i>qacE</i> , <i>catB3</i> | JAFEXB0000000000 |
| ECO52846 | Decubitus | Jičín | <i>E. coli</i> | 128, R | ND | O_H_ | 43/197 | IncR | 2558/unknown | <i>chuA</i> , <i>clbB</i> , <i>cnf1</i> , <i>focC</i> , <i>fyuA</i> , <i>gad</i> , <i>hra</i> , <i>ibea</i> , <i>iroN</i> , <i>irp2</i> , <i>iss</i> , <i>kpsE</i> , <i>kpsMII</i> , <i>mchB</i> , <i>mchC</i> , <i>mchF</i> , <i>mcmA</i> , <i>ompT</i> , <i>papA</i> , <i>FT3</i> , <i>papC</i> , <i>pic</i> , <i>stfA</i> , <i>stfA</i> , <i>terC</i> , <i>usp</i> , <i>vat</i> , <i>yfcV</i> | <i>aac(6)-Ib3</i> , <i>aac(6)-Ib-cr</i> , <i>mph(A)</i> , <i>sul-1</i> , <i>ARR-3</i> , <i>bla_{RFC-3}</i> , <i>bla_{OXA-1}</i> , <i>qacE</i> , <i>catB3</i> | JAPJVD0000000000 |
| ECO53083 ^b | Stool | Hradec Králove | <i>E. coli</i> | 8, S | ND | O_H_ | 40/30 | IncFII(K), IncR | ST131/43 | <i>chuA</i> , <i>fyuA</i> , <i>gad</i> , <i>iha</i> , <i>irp2</i> , <i>iss</i> , <i>kpsE</i> , <i>ompT</i> , <i>sat</i> , <i>stfA</i> , <i>terC</i> , <i>traT</i> , <i>usp</i> , <i>yfcV</i> | <i>aph(3)-Ib</i> , <i>aac(6)-Ib3</i> , <i>aph(6)-Id</i> , <i>aac(6)-Ib-cr</i> , <i>mph(A)</i> , <i>sul-1</i> , <i>sul-2</i> , <i>dfra14</i> , <i>ARR-3</i> , <i>bla_{RFC-3}</i> , <i>bla_{OXA-1}</i> , <i>qacE</i> , <i>catB3</i> | CP070587-CP070593 |
| CFR67526 | NA | NA | <i>C. freundii</i> | 128, R | ND | NA | NA | IncR, pKPC-CAV1321 | ST19 | <i>iss</i> , <i>kpsE</i> , <i>kpsMII</i> , <i>mchB</i> , <i>mchC</i> , <i>mchF</i> , <i>mcmA</i> , <i>ompT</i> , <i>papA</i> , <i>FT3</i> , <i>papC</i> , <i>pic</i> , <i>stfA</i> , <i>stfA</i> , <i>terC</i> , <i>usp</i> , <i>vat</i> , <i>yfcV</i> | <i>aac(6)-Ib-cr</i> , <i>mcr-9</i> , <i>mph(A)</i> , <i>sul-1</i> , <i>ARR-3</i> , <i>bla_{RFC-3}</i> , <i>bla_{OXA-1}</i> | JAPJVE0000000000 |
| CFRC0593595 | Urine | Pilsen | <i>C. freundii</i> | 128, R | ND | NA | NA | IncFIB, IncFII, IncI | ST98 | <i>chuA</i> , <i>clbB</i> , <i>cnf1</i> , <i>focC</i> , <i>fyuA</i> , <i>gad</i> , <i>hra</i> , <i>ibea</i> , <i>iroN</i> , <i>irp2</i> , <i>iss</i> , <i>kpsE</i> , <i>kpsMII</i> , <i>mchB</i> , <i>mchC</i> , <i>mchF</i> , <i>mcmA</i> , <i>ompT</i> , <i>papA</i> , <i>FT3</i> , <i>papC</i> , <i>pic</i> , <i>stfA</i> , <i>stfA</i> , <i>terC</i> , <i>usp</i> , <i>vat</i> , <i>yfcV</i> | <i>aac(6)-Ib-cr</i> , <i>aph(6)-Id</i> , <i>aph(3)-Ib</i> , <i>aac(6)-Ib-cr</i> , <i>mcr-9</i> , <i>mph(A)</i> , <i>sul-1</i> , <i>ARR-3</i> , <i>bla_{RFC-3}</i> , <i>bla_{OXA-1}</i> | JAPJVF0000000000 |
| CFR47654 | Urine | Prague | <i>C. freundii</i> | >128, R | ND | NA | NA | IncFIB, IncI | ST98 | <i>chuA</i> , <i>clbB</i> , <i>cnf1</i> , <i>focC</i> , <i>fyuA</i> , <i>gad</i> , <i>hra</i> , <i>ibea</i> , <i>iroN</i> , <i>irp2</i> , <i>iss</i> , <i>kpsE</i> , <i>kpsMII</i> , <i>mchB</i> , <i>mchC</i> , <i>mchF</i> , <i>mcmA</i> , <i>ompT</i> , <i>papA</i> , <i>FT3</i> , <i>papC</i> , <i>pic</i> , <i>stfA</i> , <i>stfA</i> , <i>terC</i> , <i>usp</i> , <i>vat</i> , <i>yfcV</i> | <i>aac(6)-Ib-cr</i> , <i>aph(6)-Id</i> , <i>aph(3)-Ib</i> , <i>aac(6)-Ib-cr</i> , <i>mcr-9</i> , <i>mph(A)</i> , <i>sul-1</i> , <i>ARR-3</i> , <i>bla_{RFC-3}</i> , <i>bla_{OXA-1}</i> | JAPJVG0000000000 |
| CFR50714 ^c | Urine | Prague | <i>C. freundii</i> | 64, R | ND | NA | NA | IncFII/IncN | ST673 | <i>chuA</i> , <i>clbB</i> , <i>cnf1</i> , <i>focC</i> , <i>fyuA</i> , <i>gad</i> , <i>hra</i> , <i>ibea</i> , <i>iroN</i> , <i>irp2</i> , <i>iss</i> , <i>kpsE</i> , <i>kpsMII</i> , <i>mchB</i> , <i>mchC</i> , <i>mchF</i> , <i>mcmA</i> , <i>ompT</i> , <i>papA</i> , <i>FT3</i> , <i>papC</i> , <i>pic</i> , <i>stfA</i> , <i>stfA</i> , <i>terC</i> , <i>usp</i> , <i>vat</i> , <i>yfcV</i> | <i>aac(6)-Ib3</i> , <i>aph(3)-Ib</i> , <i>aac(6)-Ib-cr</i> , <i>aadA1</i> , <i>fosA7.9</i> , <i>qnrS1</i> , <i>dfra14</i> , <i>sul-1</i> , <i>sul-2</i> , <i>bla_{CMV-78F}</i> | JAJFDB0000000000 |
| CFR47299 ^d | Rectal swab | Prague | <i>C. freundii</i> | 128, R | ND | NA | NA | IncC, IncFII, IncH12, IncH2A, IncN | ST65 | <i>chuA</i> , <i>clbB</i> , <i>cnf1</i> , <i>focC</i> , <i>fyuA</i> , <i>gad</i> , <i>hra</i> , <i>ibea</i> , <i>iroN</i> , <i>irp2</i> , <i>iss</i> , <i>kpsE</i> , <i>kpsMII</i> , <i>mchB</i> , <i>mchC</i> , <i>mchF</i> , <i>mcmA</i> , <i>ompT</i> , <i>papA</i> , <i>FT3</i> , <i>papC</i> , <i>pic</i> , <i>stfA</i> , <i>stfA</i> , <i>terC</i> , <i>usp</i> , <i>vat</i> , <i>yfcV</i> | <i>aph(6)-Id</i> , <i>aph(3)-Ib</i> , <i>aac(6)-Ib</i> , <i>aac(6)-Ib-cr</i> , <i>aac(3)-IIa</i> , <i>ARR-3</i> , <i>qnrA1</i> , <i>sul-1</i> , <i>sul-2</i> , <i>dfra19</i> , <i>tet(B)</i> , <i>bla_{RFC-3}</i> | JAFEFW0000000000 |
| CFR47462 ^d | Rectal swab | Prague | <i>C. freundii</i> | 128, R | ND | NA | NA | IncFII, IncH12, IncH2A, IncN, IncR | ST65 | <i>chuA</i> , <i>clbB</i> , <i>cnf1</i> , <i>focC</i> , <i>fyuA</i> , <i>gad</i> , <i>hra</i> , <i>ibea</i> , <i>iroN</i> , <i>irp2</i> , <i>iss</i> , <i>kpsE</i> , <i>kpsMII</i> , <i>mchB</i> , <i>mchC</i> , <i>mchF</i> , <i>mcmA</i> , <i>ompT</i> , <i>papA</i> , <i>FT3</i> , <i>papC</i> , <i>pic</i> , <i>stfA</i> , <i>stfA</i> , <i>terC</i> , <i>usp</i> , <i>vat</i> , <i>yfcV</i> | <i>aph(6)-Id</i> , <i>aph(3)-Ib</i> , <i>aac(6)-Ib</i> , <i>aac(6)-Ib-cr</i> , <i>aac(3)-IIa</i> , <i>ARR-3</i> , <i>qnrA1</i> , <i>sul-1</i> , <i>sul-2</i> , <i>dfra19</i> , <i>tet(B)</i> , <i>bla_{RFC-3}</i> | JAFEFW0000000000 |

(Continued on next page)

TABLE 1 (Continued)

| Strain | Origin | Location | Species | FOS MIC ($\mu\text{g/ml}$) and category | FosA variant | Serotype | FumC/FimH | Plasmid | ST (Oxford/Pasteur) | Virulence genes | Other resistance genes | Accession no. |
|-----------------------|-------------|----------|--------------------|---|--------------|----------|-----------|------------------------|---------------------|-----------------|---|-------------------|
| CFR56415 ^c | Rectal swab | Prague | <i>C. freundii</i> | 8, S | ND | NA | NA | IncH12, IncH12A | ST95 | NA | <i>bla</i> _{OXK-48} , <i>bla</i> _{TEM-1b} , <i>bla</i> _{OXK-17} , <i>qacE</i> , <i>catB3</i> , <i>catA1</i> , <i>aadA1</i> , <i>ant(2'')</i> -Ia, <i>aph(3'')</i> -Ia, <i>aac(6)-Ib-cr</i> , <i>aadA2b</i> , <i>aac(6)-Ib3</i> , <i>mcr-9</i> , <i>sul-1</i> , <i>dfra19</i> , <i>bla</i> _{NDK-47} , <i>bla</i> _{NDK-57} , <i>qacE</i> , <i>cmiA1</i> , <i>catA2</i> , <i>aac(6)-Ib-cr</i> , <i>aadA1</i> , <i>ant(2'')</i> -Ia, <i>aph(3'')</i> -Ia, <i>aac(6)-Ib3</i> , <i>aadA1</i> , <i>aadA2b</i> , <i>aac(3)-I</i> , <i>mcr-9</i> , <i>qnrA1</i> , <i>sul-1</i> , <i>dfra19</i> , <i>tet(A)</i> , <i>bla</i> _{NDK-57} , <i>bla</i> _{NDK-47} , <i>qacE</i> , <i>catA2</i> , <i>cmiA1</i> , <i>aac(3'')</i> -Ia, <i>aac(6)-Ib-cr</i> , <i>aph(6)-Ia</i> , <i>aph(3'')</i> -Ib, <i>qnrB1</i> , <i>dfra14</i> , <i>sul2</i> , <i>tet(A)</i> , <i>tet(D)</i> , <i>bla</i> _{OXK-48} , <i>bla</i> _{CTX-M-15'} , <i>bla</i> _{TEM-1BP} , <i>bla</i> _{OXK-17} , <i>bla</i> _{NDK-109} , <i>catB3</i> | CP085726–CP085728 |
| CFR51929 ^c | Rectal swab | Prague | <i>C. freundii</i> | 16, S | ND | NA | NA | IncH12, IncH12A, IncM1 | ST95 | NA | | CP059427–CP059429 |
| CFR47298 | Decubitus | Prague | <i>C. freundii</i> | >128, R | ND | NA | NA | IncFIB, IncL | ST98 | NA | | JARWKP000000000 |

^aNA, not available; ND, not detected; *air*, enteroaggregative immunoglobulin repeat protein; *chuA*, outer membrane hemin receptor; *eilA*, *Salmonella* HIIA homolog; *fyu*, siderophore yersiniabactin receptor; *gad*, glutamate decarboxylase; *irp2*, high-molecular-weight protein 2 nonribosomal peptide synthetase; *is*, increased serum survival; *kpsE*, capsule polysaccharide export inner membrane protein; *kpsMII_K5*, polysialic acid transport protein; *lpfA*, long polar fimbriae; *ompT*, outer membrane protease; *terC*, tellurium ion resistance protein; *traT*, outer membrane complement resistance; *ycfY*, fimbria-like protein.

^bPublished in reference 36.

^cIncluded in reference 77.




FIG 2 Linear map of the *fosA10* genetic environment of p542093_1, the genetic environment of the *fosA10*-carrying plasmid isolated from ECO49406, and the genetic environment of *fosA10* harbored on an IncFII pHNPk9-Fos. Arrows show the direction of transcription of open reading frames. *exxA*, mobile elements, *fosA10*, and other remaining genes are designated by blue, yellow, red, and brown, respectively. Gray shading shows homologous segments with 100% sequence identity.

Fosfomycin pathway alterations. Fifteen sequenced strains were investigated for the presence of point mutations in proteins involved in the FOS pathway. When possible, strains of the same ST but different FOS profiles were compared. Concerning *E. coli* strains, three of six belonged to ST131, two to ST2558, and one to ST648 (Fig. 7; also, see Fig. S1 in the supplemental material).

All three ST131 *E. coli* isolates shared neutral substitutions in the amino acids of GlpT, UhpT, UhpB, CyaA, PtsI, GlpR, UhpC, PtsG, and GlpQ (Fig. 7). Additionally, two FOS-resistant (FOS^r) strains (strains ECO52246 and ECO52259) out of three ST131 strains showed a deleterious W28del (PROVEAN [P] score, -12,042) of GlpT. On the other hand, the remaining FOS-susceptible (FOS^s) ST131 strain (ECO53083) carried a deleterious substitution (P score, -3.919) in GlpR (A86E) (Fig. 7).

Two *E. coli* ST2558 strains (FOS^r strain ECO528469 and FOS^s strain ECO52550) shared the same neutral substitutions in GlpT, UhpB, CyaA, PtsI, GlpR, UhpC, and GlpQ. Moreover, both ST2558 strains showed a deleterious substitution (P score, -3.077) in CyaA (G359E).

The FosA10-producing strain ECO49406 exhibited a wide range of single amino acid substitutions, categorized as neutral, in GlpT, UhpB, CyaA, PtsI, and GlpR. ECO49406 carried




FIG 3 Alignment of amino acid sequences of the FosA7 variants: FosA7 (WP_000941934.1) (94.29% identity with FosA7.9), FosA7.2 (WP_000941935.1) (94.29% identity), FosA7.3 (WP_023231494.1) (93.57% identity), FosA7.4 (WP_023216493.1) (95%), FosA7.5 (WP_000941933.1) (93.57%), FosA7.6 (WP_061377147.1) (93.57%), FosA7.7 (WP_058653118.1) (93.57%), FosA7.8 (WP_079820715.1) (92.86%), and FosA7.9 (UYP40110.1).




FIG 4 The evolutionary analysis and phylogenetic tree of FosA proteins found in *Enterobacteriales* were inferred by using the maximum-likelihood method and JTT matrix-based model using MEGA 11. The tree with the highest log likelihood ($-1,275.39$) is shown. The percentage of trees in which the associated taxa clustered together is shown above the branches. The tree is drawn to scale. The red rectangle indicates the new FosA7.9 in *C. freundii*.

the deleterious mutation G359E (P score, -3.077) in CyaA (Fig. 7). No alteration in the target MurA, the transporter UhpT, or the regulators PtsH, UhpA, UhpC, FNR (fumarate and nitrate reduction regulatory protein), and CRR were detected in any of the *E. coli* strains studied. These results imply a link between ST and mutations in the FOS pathway.

Regarding *C. freundii* isolates, three of nine belonged to ST98, two to ST95, two to ST65, one to ST673, and one to ST19. Analysis of the FOS pathway highlighted a similar link between ST and certain amino acid substitutions (Fig. 8). Two FOS^r ST65 strains (CFR47299 and CFR47462) shared the same neutral substitutions in GlpT, UhpB, CyaA, UhpC, and GlpQ. Additionally, both isolates missed the first 4 amino acids (aa) (MLSI) and had the deleterious substitutions K6L, P7N, and A8Q (P scores, -4.8 , -8.2 , and -3.4 , respectively) in GlpT. Two FOS^s ST95 strains (CFR56415 and CFR51929) accumulated identical neutral substitutions in UhpB, CyaA, UhpC, and PtsG but shared the deleterious mutation V766A in CyaA (P score, -3.13). The same deleterious change in CyaA occurred in strains CFR47298 and CFR50714, belonging to ST98 and ST673, respectively. In contrast, strain CFR47298 had deleterious deletions in GlpT (Y406del; P score, -11.6) and in UhpC (F112L; P score, -5.28). Strain CFR67526, the only ST19 strain, shared the same reported neutral alteration in CyaA. Interestingly, the *glpT* sequence had an insertion of 25 nucleotides (nt) at position 788, leading to a 1,384-nt instead of a 1,359-nt gene.




FIG 5 Linear map of the *fic* cassette genetic environment of SCAID-URN1-2019 and BAA-895, the genetic environment of the *fosA7.9* cassette harbored on the CFR50714 chromosome, L75, and RHBSTW-00135. Arrows show the direction of transcription of ORFs. The *fic* family, HNH endonuclease, *fosA7.9*, type II restriction, DNA-cytosine methyltransferase, AAA domain, and other genes are designated by light blue, yellow, red, fuchsia, green, blue and brown, respectively. Homologous segments are indicated with gray shading (light gray, 94% sequence identity; dark gray, 100% identity).

The frameshift mutation affects the amino acids from position 251 to 263aa, which could possibly affect the activity of the transporter (Fig. 8). No alterations in MurA and in the regulators UhpA, PtsH, PtsI, GlpR, CRP, and CRR were detected in any of the *C. freundii* strains studied. These results together show that the occurrence of mutations at different levels can decrease FOS susceptibility.

DISCUSSION

Fosfomycin has regained importance in clinical practice and has offered an alternative first-line option against MDR bacterial infections. The pathway of fosfomycin inside bacterial cells depends mainly on GlpT and UhpT activity (2). Acquiring mutations in GlpT and UhpT can impair their transport activity, decreasing FOS uptake into the bacterial cell and hence FOS effectiveness (41–43). However, modifications in these proteins have a high fitness cost, leading to the predominance of FOS-susceptible strains (44).

In the current study, all sequenced *E. coli* strains had amino acid substitutions in GlpT. The substitutions E448K, Q444E, and E443Q, categorized as neutral by PROVEAN, were reported previously by Takahata et al. and Sorlozano-Puerto et al. and are recognized as not impacting GlpT functionality (3, 9). L297F has been categorized as neutral (P score, -2.375) and was reported previously by Sorlozano-Puerto and colleagues (9); however, the impact on GlpT function has not been investigated yet. Two FOS^r *E. coli* ST131 strains (ECO52246 and ECO52259) contained W28del, classified as deleterious (P score, -12.042). We speculate that there is a possible impact of W28del on GlpT activity, leading to a FOS^r profile in *E. coli* ST131 strains. *E. coli* ST131 is a hypervirulent and pandemic clone (45) associated with the global spread of ESBLs such as CTX-M-15, KPC-like, and NDM-like enzymes (46–48). The acquisition of additional antimicrobial resistance traits in such successful clones can impact the clinical outcome of infections by such isolates and reduce antibiotic availability.

UhpB is a component of the UhpABC system and is a membrane-associated protein kinase that autophosphorylates and subsequently transfers its phosphate group to




FIG 6 Phylogenetic tree of the nine *C. freundii* isolates with 103 genomes downloaded from the NCBI database. Red nodes indicate the isolates harboring *fosA7.9* variants. The red square shows the studied isolates. Gray triangles indicate collapsed nodes.

UhpA, activating it. CyaA is an adenylate cyclase and catalyzes the formation of cAMP from ATP. UhpB and CyaA exhibited a consistent number of alterations, most of them categorized as neutral. Interestingly, all sequenced *E. coli* isolates carried the single amino acid substitution M1L (P score, -1.581) but without a clear impact on CyaA functionality. Moreover, three *E. coli* strains, two FOS^r (ECO49406 and ECO52846) and one FOS^s (ECO52550), carried the deleterious mutation G359E (P score, -3.077). We hypothesize that this substitution could affect CyaA activity but without leading to a FOS^r event at a high level. We hypothesize that in the presence of G359E CyaA, other mechanisms can be involved, leading to the FOS^r profiles in these *E. coli* strains.

GlpR is a repressor of GlpT that binds to G3P, which is essential for *glpT* transcription. In the literature, studies concerning the eventual effect of GlpR on FOS MIC have not been reported yet. Here, we report the deleterious mutation A86E in GlpR. This alteration occurred in a FOS^s *E. coli* ST131 strain (MIC = 8 [susceptible {S}]), and we speculated that there is a possible effect on GlpR activity, leading to the increased FOS MIC. Our findings highlight the possible role that GlpR plays in FOS susceptibility in *E. coli* strains. Further investigations are needed to understand the nature of the role of GlpR in altering FOS MIC.

In the literature, there are no reports that evaluate modifications in FOS pathway among *Citrobacter* spp.

Here, we describe the first genetic analysis of mutations detected in FOS^s and FOS^r *C. freundii* isolates and their effect on FOS susceptibility. In our study, several amino




FIG 9 (A) Map of the Czech Republic. (B) Regional percentage of collected isolates (values expressed in percentage).

new FosA7 allele, FosA7.9, in *C. freundii* in the Czech Republic. The emergence and the spread of both chromosome- and plasmid-mediated FOS^r mechanisms in CRE could compromise the usefulness of FOS against severe and complex infections. A better knowledge of the genetic mechanisms underlying FOS^r may facilitate the creation of rapid DNA-based testing for FOS^r.

MATERIALS AND METHODS

Identification of bacterial isolates, susceptibility determination, and detection of enzymes. In the period from December 2018 to February 2022, 223 carbapenemase-producing *E. coli* isolates and 70 *Citrobacter* isolates (64 *C. freundii*, 3 *Citrobacter amalonaticus*, 2 *Citrobacter braakii*, and 1 *Citrobacter youngae* isolate) were collected from different health care settings in the Czech Republic and sent to University Hospital in Pilsen, Czech Republic, as part of a national surveillance effort for carbapenemase production in *Enterobacterales* (Fig. 9A and B). Of these, 51.1% (150/293) were collected from urine, 19% (56/293) from rectal swabs, 8% (23/293) from wounds, 8% (23/293) from sputum, 2% (6/293) from blood, and the remaining 11.9% (35/293) from different sources, including stool, pus, bronchoalveolar lavage fluid, decubitus swabs, throat swabs, and aspirates (Fig. S2).

Identification of strains was confirmed by matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) with MALDI Biotyper software (Bruker Daltonics, Bremen, Germany). The production of carbapenemases (metallo- β -lactamase, OXA-48, and KPC) was assessed with the double-disc synergy test with EDTA, the temocillin disc test, and the phenylboronic acid test (37). FOS MICs were evaluated using ADM and interpreted according to EUCAST clinical breakpoints (v 12.0) and guidelines. Production of FosA-like and FosC2 enzymes was detected by the PPF test (60).

Molecular investigations. All the isolates were screened by PCR for the presence of *bla*_{KPC-like}, *bla*_{NDM-like}, *bla*_{VIM-like}, and *bla*_{OXA-48-like} genes, as reported elsewhere (36). Positive strains with PPF test were additionally screened by PCR for the presence of *fosA*, *fosA2*, *fosA3*, *fosA4*, *fosA5*, *fosA6*, *fosA7*, *fosA10*, and *fosC2* (15, 16, 21, 61).

WGS and analysis. A total of 15 strains (6 *E. coli* and 9 *C. freundii* strains) were selected as representative for genomic content and FOS pathway mutation analysis. The selection was based on FOS MICs: the selection included 11 strains (four *E. coli* and seven *C. freundii* strains) with FOS MICs of ≥ 64 $\mu\text{g}/\text{mL}$ (resistant [R]) and four strains (two *E. coli* and two *C. freundii* strains) with FOS MICs of ≤ 16 $\mu\text{g}/\text{mL}$ (S). The four FOS-susceptible strains were included to compare differences in FOS^r and FOS susceptibility (FOS^s) profiles. In detail, the selection for FOS^s *E. coli* included FOS MICs corresponding to the FOS epidemiological cutoff (ECOFF) value and one dilution beyond the FOS ECOFF value according to EUCAST (https://mic.eucast.org/search/?search%5Bmethod%5D=mic&search%5Bantibiotic%5D=100&search%5Bspecies%5D=-1&search%5Bdisk_content%5D=-1&search%5Blimit%5D=50). For FOS^s *C. freundii* isolates, FOS ECOFF values are not available; thus, low-level susceptibility profiles for FOS were selected (FOS MIC = 8 $\mu\text{g}/\text{mL}$ and 16 $\mu\text{g}/\text{mL}$).

Genomic DNA was extracted using a NucleoSpin microbial DNA kit (Macherey-Nagel, Germany). WGS was performed on seven selected strains with the NovaSeq 6000 system with a 2×250 paired-end run following Nextera XT library preparation (Illumina Inc., San Diego, CA, USA). The remaining eight strains belonged to two different projects (Table 1), and WGS was previously performed with both the Illumina MiSeq platform (Illumina Inc., San Diego, CA, USA) and the Sequel I platform (Pacific Biosciences, Menlo Park, CA, USA) (36). Reads were assembled using SPAdes software (62). Assembled sequences were annotated using the RAST (Rapid Annotation using Subsystems Technology) server (63). The resistome, plasmid replicons, mobile elements, multilocus sequence types (MLST), and plasmid MLST (pMLST) were determined by uploading the assembled sequences to ResFinder 4.1 and CARD (64, 65), PlasmidFinder (66), ISfinder (67), MLST 2.0 (68), and pMLST 2.0 (66), respectively. Comparative genome alignment was done using Mauve v.2.4.0 and SnapGene (SnapGene Software). A linear map of

chromosomal environments was created by using EasyFig (69) and the graphic editor Procreate (Savage Interactive, Tasmania, Australia).

Phylogenetic analysis. Phylogenetic relationships between the selected sequenced isolates and global genomes were investigated. Phylogenetic trees were obtained using core genome, recombination, and SNPs by using parsnp v1.2, available in the harvest suite (70), and using a corresponding reference genome. Graphic illustration of the trees was built with the Interactive Tree Of Life (iTOL) (<https://itol.embl.de/>) (71). For the construction of the SNP-based phylogenies, 160 *Escherichia coli* genomes and 112 *Citrobacter freundii* genomes were downloaded from the NCBI assembly database, including complete and draft genomes. *E. coli* ECO49406 and *C. freundii* RHBSTW-00135 were used as respective references. The evolutionary analysis of FosA-like proteins in *Enterobacteriales* was conducted by MEGA 11 (72), using the maximum-likelihood method and the Jones-Taylor-Thornton (JTT) matrix-based model (73).

Conjugation/transformation assay. The conjugal transfer of *fosA* genes was tested in liquid medium using the *E. coli* A15 strain (Azd^r) as a recipient. Transconjugants were selected on MacConkey agar (Scharlab, SL, Barcelona, Spain) plates containing sodium azide (100 mg/L) (Sigma-Aldrich, St. Louis, MO, USA), FOS (64 mg/L) (Sigma-Aldrich), and G6P (25 mg/L) (Roche). The presence of *fosA*-like genes and the plasmid content in transconjugants were further confirmed by PCR and PCR replicon typing (PBRT 2.0 kit), respectively (74). Since *fosA7* was not transferable by conjugation, transformation was carried out with CFR50714; plasmid extraction was performed using a Qiagen maxi kit (Qiagen, Hilden, Germany), and competent *E. coli* Top10 cells were used as the recipient. Transformants were selected on Mueller-Hinton (MH) agar (Oxoid, Hampshire, UK) with 32 mg/L FOS (Sigma-Aldrich) and 25 mg/L G6P (Roche) (75).

Protein mutations. The effects of amino acid alterations on the biological function were predicted using the online PROVEAN (Protein Variation Effect Analyzer) platform (<http://provean.jcvi.org/index.php>) (76). PROVEAN predicts protein sequence variations, including single or multiple amino acid substitutions, insertions, or deletions. The platform produces a delta alignment score based on the reference and variant versions of a protein query sequence with respect to sequence homologs collected from the NCBI protein database through BLAST. For each substitution, the tool provides a score (P score) categorized in three classes: (i) if the P score is equal to or below the cutoff of -2.5 , the protein alteration is categorized as deleterious (potential loss of protein structure or function); (ii) if the P score is above the threshold, the alteration is marked as neutral (no alteration in the structure or function of the protein) (9). Amino acid variations in MurA, GlpT, UhpT, UhpA, UhpB, UhpC, CyaA, PtsI, PtsH (phosphocarrier protein HPr), GlpR, CRP, CRR (enzyme IIA [Glc]), PtsG (phosphotransferase system [PTS] glucose-specific EII_{CB} component), FNR (fumarate and nitrate reduction regulatory protein), and GlpQ (glycerophosphodiester phosphodiesterase) were investigated (accession numbers are reported in Table S1).

Data availability. The nucleotide sequence of *fosA7.9* has been uploaded to GenBank under the accession number [ON245013](https://www.ncbi.nlm.nih.gov/nuclseq/ON245013). GenBank accession numbers of the sequenced strains are presented in Table 1.

ACKNOWLEDGMENTS

The study was supported by research project grants NU20J-05-00033 and NU23J-09-00067 provided by the Czech Health Research Council and by the project National Institute of Virology and Bacteriology (Program EXCELES, ID project no. LX22NPO5103), funded by the European Union–Next Generation EU.

REFERENCES

- Dijkmans AC, Zacarias NVO, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C, Touw DJ, Stevens J, Kamerling IMC. 2017. Fosfomycin: pharmacological, clinical and future perspectives. *Antibiotics* 6:24. <https://doi.org/10.3390/antibiotics6040024>.
- Castañeda-García A, Blázquez J, Rodríguez-Rojas A. 2013. Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance. *Antibiotics (Basel)* 2:217–236. <https://doi.org/10.3390/antibiotics2020217>.
- Takahata S, Ida T, Hiraishi T, Sakakibara S, Maebashi K, Terada S, Muratani T, Matsumoto T, Nakahama C, Tomono K. 2010. Molecular mechanisms of fosfomycin resistance in clinical isolates of *Escherichia coli*. *Int J Antimicrob Agents* 35:333–337. <https://doi.org/10.1016/j.ijantimicag.2009.11.011>.
- Zeng J, Hong Y, Zhao N, Liu Q, Zhu W, Xiao L, Wang W, Chen M, Hong S, Wu L, Xue Y, Wang D, Niu J, Drlíca K, Zhao X. 2022. A broadly applicable, stress-mediated bacterial death pathway regulated by the phosphotransferase system (PTS) and the cAMP-Crp cascade. *Proc Natl Acad Sci U S A* 119:e2118566119. <https://doi.org/10.1073/pnas.2118566119>.
- Kimata K, Takahashi H, Inada T, Postma P, Aiba H. 1997. cAMP receptor protein-cAMP plays a crucial role in glucose-lactose diauxie by activating the major glucose transporter gene in *Escherichia coli*. *Proc Natl Acad Sci U S A* 94:12914–12919. <https://doi.org/10.1073/pnas.94.24.12914>.
- Kurabayashi K, Tanimoto K, Tomita H, Hirakawa H. 2017. Cooperative actions of CRP-cAMP and FNR increase the fosfomycin susceptibility of enterohaemorrhagic *Escherichia coli* (EHEC) by elevating the expression of *glpT* and *uhpT* under anaerobic conditions. *Front Microbiol* 8:426. <https://doi.org/10.3389/fmicb.2017.00426>.
- Seeto S, Notley-McRobb L, Ferenci T. 2004. The multifactorial influences of RpoS, Mlc and cAMP on ptsG expression under glucose-limited and anaerobic conditions. *Res Microbiol* 155:211–215. <https://doi.org/10.1016/j.resmic.2003.11.011>.
- Ohshima N, Yamashita S, Takahashi N, Kuroishi C, Shiro Y, Takio K. 2008. *Escherichia coli* cytosolic glycerophosphodiester phosphodiesterase (UgpQ) requires Mg²⁺, Co²⁺, or Mn²⁺ for its enzyme activity. *J Bacteriol* 190:1219–1223. <https://doi.org/10.1128/JB.01223-07>.
- Sorlozano-Puerto A, Lopez-Machado I, Albertuz-Crespo M, Martinez-Gonzalez LJ, Gutierrez-Fernandez J. 2020. Characterization of fosfomycin and nitrofurantoin resistance mechanisms in *Escherichia coli* isolated in clinical urine samples. *Antibiotics* 9:534. <https://doi.org/10.3390/antibiotics9090534>.
- Kadner RJ. 1973. Genetic control of the transport of hexose phosphates in *Escherichia coli*: mapping of the *uhp* locus. *J Bacteriol* 116:764–770. <https://doi.org/10.1128/jb.116.2.764-770.1973>.
- Tsuruoka T, Yamada Y. 1975. Characterization of spontaneous fosfomycin (phosphonomycin)-resistant cells of *Escherichia coli* B in vitro. *J Antibiot (Tokyo)* 28:906–911. <https://doi.org/10.7164/antibiotics.28.906>.
- Zurfluh K, Treier A, Schmitt K, Stephan R. 2020. Mobile fosfomycin resistance genes in Enterobacteriaceae—an increasing threat. *Microbiolgyopen* 9:e1135. <https://doi.org/10.1002/mbo3.1135>.
- Zou M, Ma PP, Liu WS, Liang X, Li XY, Li YZ, Liu BT. 2021. Prevalence and antibiotic resistance characteristics of extraintestinal pathogenic *Escherichia coli* among healthy chickens from farms and live poultry markets in China. *Animals* 11:1112. <https://doi.org/10.3390/ani11041112>.

14. Huang L, Cao M, Hu Y, Zhang R, Xiao Y, Chen G. 2021. Prevalence and mechanisms of fosfomycin resistance among KPC-producing *Klebsiella pneumoniae* clinical isolates in China. *Int J Antimicrob Agents* 57:106226. <https://doi.org/10.1016/j.ijantimicag.2020.106226>.
15. Loras C, González-Prieto A, Pérez-Vázquez M, Bautista V, Ávila A, Campoy PS, Oteo-Iglesias J, Alós JI. 2021. Prevalence, detection and characterisation of fosfomycin-resistant *Escherichia coli* strains carrying fosA genes in Community of Madrid, Spain. *J Glob Antimicrob Resist* 25:137–141. <https://doi.org/10.1016/j.jgar.2021.02.032>.
16. Huang Y, Lin Q, Zhou Q, Lv L, Wan M, Gao X, Wang C, Liu JH. 2020. Identification of fosA10, a novel plasmid-mediated fosfomycin resistance gene of *Klebsiella pneumoniae* origin, in *Escherichia coli*. *Infect Drug Resist* 13: 1273–1279. <https://doi.org/10.2147/IDR.S251360>.
17. Singkham-In U, Muhummudaree N, Chatsuwat T. 2020. fosA3 overexpression with transporter mutations mediates high-level of fosfomycin resistance and silence of fosA3 in fosfomycin-susceptible *Klebsiella pneumoniae* producing carbapenemase clinical isolates. *PLoS One* 15:e0237474. <https://doi.org/10.1371/journal.pone.0237474>.
18. Zhang LJ, Gu XX, Zhang J, Yang L, Lu YW, Fang LX, Jiang HX. 2020. Characterization of a fosA3 carrying IncC-IncN plasmid from a multidrug-resistant ST17 *Salmonella* Indiana isolate. *Front Microbiol* 11:1582. <https://doi.org/10.3389/fmicb.2020.01582>.
19. Wang H, Min C, Li J, Yu T, Hu Y, Dou Q, Zou M. 2021. Characterization of fosfomycin resistance and molecular epidemiology among carbapenem-resistant *Klebsiella pneumoniae* strains from two tertiary hospitals in China. *BMC Microbiol* 21:109. <https://doi.org/10.1186/s12866-021-02165-7>.
20. Rehman MA, Yin X, Persaud-Lachman MG, Diarra MS. 2017. First detection of a fosfomycin resistance gene, fosA7, in *Salmonella enterica* serovar Heidelberg isolated from broiler chickens. *Antimicrob Agents Chemother* 61:e00410-17. <https://doi.org/10.1128/AAC.00410-17>.
21. Wang J, Wang Y, Wang ZY, Wu H, Mei CY, Shen PC, Pan ZM, Jiao X. 2021. Chromosomally located fosA7 in *Salmonella* isolates from China. *Front Microbiol* 12:781306. <https://doi.org/10.3389/fmicb.2021.781306>.
22. Sun Y, Chen W, Wang S, Cao X. 2021. Co-occurrence of fosA5, bla_{SHV-145} and bla_{OXA-48} among a *Klebsiella pneumoniae* high-risk ST16 from a tertiary hospital in China: focusing on the phylogeny of OXA-48 genes from global *Klebsiella pneumoniae* isolates. *Braz J Microbiol* 52:2559–2563. <https://doi.org/10.1007/s42770-021-00572-6>.
23. Gou JJ, Liu N, Guo LH, Xu H, Lv T, Yu X, Chen YB, Guo XB, Rao YT, Zheng BW. 2020. Carbapenem-resistant Enterobacter hormaechei ST1103 with IMP-26 carbapenemase and ESBL gene bla_{SHV-178}. *Infect Drug Resist* 13: 597–605. <https://doi.org/10.2147/IDR.S232514>.
24. Sajeev S, Hamza M, Sivaraman GK, Ghatak S, Ojha R, Mendem SK, Murugesan D, Raisen C, Shome BR, Holmes MA. 2022. Genomic insights of beta-lactamase producing *Klebsiella quasipneumoniae* subsp. *similipneumoniae* belonging to sequence type 1699 from retail market fish, India. *Arch Microbiol* 204:454. <https://doi.org/10.1007/s00203-022-03071-w>.
25. Biggel M, Zurfluh K, Treier A, Nüesch-Inderbinen M, Stephan R. 2021. Characteristics of fosA-carrying plasmids in *E. coli* and *Klebsiella* spp. isolates originating from food and environmental samples. *J Antimicrob Chemother* 76:2004–2011. <https://doi.org/10.1093/jac/dkab119>.
26. Milner KA, Bay DC, Alexander D, Walky A, Karlowsky JA, Mulvey MR, Sharma MK, Zhanel GG. 2020. Identification and characterization of a novel FosA7 member from fosfomycin-resistant *Escherichia coli* clinical isolates from Canadian hospitals. *Antimicrob Agents Chemother* 65: e00865-20. <https://doi.org/10.1128/AAC.00865-20>.
27. ten Doesschate T, Abbott IJ, Willems RJJ, Top J, Rogers MRC, Bonten MM, Paganelli FL. 2019. In vivo acquisition of fosfomycin resistance in *Escherichia coli* by fosA transmission from commensal flora. *J Antimicrob Chemother* 74:3630–3632. <https://doi.org/10.1093/jac/dkz380>.
28. Hao Y, Zhao X, Zhang C, Bai Y, Song Z, Lu X, Chen R, Zhu Y, Wang Y. 2021. Clonal dissemination of clinical carbapenem-resistant *Klebsiella pneumoniae* isolates carrying fosA3 and bla_{KPC-2} cohabiting plasmids in Shandong, China. *Front Microbiol* 12:771170. <https://doi.org/10.3389/fmicb.2021.771170>.
29. Zhou Y, Ai W, Cao Y, Guo Y, Wu X, Wang B, Rao L, Xu Y, Zhao H, Wang X, Yu F. 2021. The co-occurrence of NDM-5, MCR-1, and FosA3-encoding plasmids contributed to the generation of extensively drug-resistant *Klebsiella pneumoniae*. *Front Microbiol* 12:811263. <https://doi.org/10.3389/fmicb.2021.811263>.
30. Xiang D-R, Li J-J, Sheng Z-K, Yu H-Y, Deng M, Bi S, Hu F-S, Chen W, Xue X-W, Zhou Z-B, Doi Y, Sheng J-F, Li L-J. 2016. Complete sequence of a novel IncR-F33:A-B- plasmid, pKP1034, harboring fosA3, blaKPC-2, blaCTX-M-65, blaSHV-12, and rmtB from an epidemic *Klebsiella pneumoniae* sequence type 11 strain in China. *Antimicrob Agents Chemother* 60: 1343–1348. <https://doi.org/10.1128/AAC.01488-15>.
31. Wang Q, Zhang P, Zhao D, Jiang Y, Zhao F, Wang Y, Li X, Du X, Yu Y. 2018. Emergence of tigecycline resistance in *Escherichia coli* co-producing MCR-1 and NDM-5 during tigecycline salvage treatment. *Infect Drug Resist* 11:2241–2248. <https://doi.org/10.2147/IDR.S179618>.
32. Peng Z, Li X, Hu Z, Li Z, Lv Y, Lei M, Wu B, Chen H, Wang X. 2019. Characteristics of carbapenem-resistant and colistin-resistant *Escherichia coli* co-producing NDM-1 and MCR-1 from pig farms in China. *Microorganisms* 7: 482. <https://doi.org/10.3390/microorganisms7110482>.
33. Tian X, Zheng X, Sun Y, Fang R, Zhang S, Zhang X, Lin J, Cao J, Zhou T. 2020. Molecular mechanisms and epidemiology of carbapenem-resistant *Escherichia coli* isolated from Chinese patients during 2002–2017. *Infect Drug Resist* 13:501–512. <https://doi.org/10.2147/IDR.S232010>.
34. Feng J, Qiu Y, Yin Z, Chen W, Yang H, Yang W, Wang J, Gao Y, Zhou D. 2015. Coexistence of a novel KPC-2-encoding MDR plasmid and an NDM-1-encoding pNDM-HN380-like plasmid in a clinical isolate of *Citrobacter freundii*. *J Antimicrob Chemother* 70:2987–2991. <https://doi.org/10.1093/jac/dkv232>.
35. Bitar I, Caltagirone M, Villa L, Mattioni Marchetti V, Nucleo E, Sarti M, Migliavacca R, Carattoli A. 2019. Interplay among IncA and bla_{KPC}-carrying plasmids in *Citrobacter freundii*. *Antimicrob Agents Chemother* 63: e02609-18. <https://doi.org/10.1128/AAC.02609-18>.
36. Kraftova L, Finianos M, Studentova V, Chudejova K, Jakubu V, Zemlickova H, Papagiannitsis CC, Bitar I, Hrabak J. 2021. Evidence of an epidemic spread of KPC-producing Enterobacteriales in Czech hospitals. *Sci Rep* 11: 15732. <https://doi.org/10.1038/s41598-021-95285-z>.
37. Chudejova K, Kraftova L, Mattioni Marchetti V, Hrabak J, Papagiannitsis CC, Bitar I. 2021. Genetic plurality of OXA/NDM-encoding features characterized from Enterobacteriales recovered from Czech hospitals. *Front Microbiol* 12:641415. <https://doi.org/10.3389/fmicb.2021.641415>.
38. Li Z, Lin Y, Lu L, Wang K, Yang L, Li P, Li J, Jia L, Li P, Song H. 2020. Genetic characterisation of a complex class 1 integron in an NDM-1-producing *Citrobacter freundii* ST396 clinical strain isolated from a urine sample. *J Glob Antimicrob Resist* 23:64–66. <https://doi.org/10.1016/j.jgar.2020.08.002>.
39. AbuOun M, Jones H, Stubberfield E, Gilson D, Shaw LP, Hubbard ATM, Chau KK, Sebra R, Peto TEA, Crook DW, Read DS, Gweon HS, Walker AS, Stoesser N, Smith RP, Anjum MF. The Rehab Consortium. 2021. A genomic epidemiological study shows that prevalence of antimicrobial resistance in Enterobacteriales is associated with the livestock host, as well as antimicrobial usage. *Microb Genom* 7:e000630. <https://doi.org/10.1099/mgen.0.000630>.
40. Korotetskiy IS, Jumagaziyeva AB, Shilov SV, Kuznetsova TV, Iskabayeva ZA, Myrzabayeva AN, Korotetskaya N, Ilin AI, Reva ON. 2020. Phenotypic and genotypic characterisation of clinical isolates of nosocomial infections. *Eurasian J Appl Biotechnol* <https://doi.org/10.11134/btp.1.2020.5>.
41. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. 1974. The mechanism of action of fosfomycin (phosphonomycin). *Ann N Y Acad Sci* 235:364–386. <https://doi.org/10.1111/j.1749-6632.1974.tb43277.x>.
42. Hardisson C, Llaneza J. 1977. The action of fosfomycin on the growth of *Pseudomonas aeruginosa*. *Chemotherapy* 23:37–44. <https://doi.org/10.1159/00022024>.
43. Lindgren V. 1978. Mapping of a genetic locus that affects glycerol 3-phosphate transport in *Bacillus subtilis*. *J Bacteriol* 133:667–670. <https://doi.org/10.1128/jb.133.2.667-670.1978>.
44. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. 2003. Biological costs and mechanisms of fosfomycin resistance in *Escherichia coli*. *Antimicrob Agents Chemother* 47:2850–2858. <https://doi.org/10.1128/AAC.47.9.2850-2858.2003>.
45. Whitmer GR, Moorthy G, Arshad M. 2019. The pandemic *Escherichia coli* sequence type 131 strain is acquired even in the absence of antibiotic exposure. *PLoS Pathog* 15:e1008162. <https://doi.org/10.1371/journal.ppat.1008162>.
46. Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe A, Sordillo EM, Lewis JS, Howard WJ, Johnson LE, Polsky B, Jorgensen JH, Richter SS, Shutt KA, Paterson DL. 2013. Community-associated extended-spectrum β -lactamase-producing *Escherichia coli* infection in the United States. *Clin Infect Dis* 56:641–648. <https://doi.org/10.1093/cid/cis942>.
47. Piazza A, Principe L, Comandatore F, Perini M, Meroni E, Mattioni Marchetti V, Migliavacca R, Luzzaro F. 2021. Whole-genome sequencing investigation of a large nosocomial outbreak caused by ST131 H30Rx KPC-producing *Escherichia coli* in Italy. *Antibiotics* 10:718. <https://doi.org/10.3390/antibiotics10060718>.
48. Peirano G, Chen L, Nobrega D, Finn TJ, Kreiswirth BN, DeVinney R, Pitout JDD. 2022. Genomic epidemiology of global carbapenemase-producing *Escherichia coli*, 2015–2017. *Emerg Infect Dis* 28:924–931. <https://doi.org/10.3201/eid2805.212535>.
49. Samuelsen Ø, Overballe-Petersen S, Bjørnholt JV, Brisse S, Doumith M, Woodford N, Hopkins KL, Aasnæs B, Haldorsen B, Sundsfjord A. Norwegian

- Study Group on CPE. 2017. Molecular and epidemiological characterization of carbapenemase-producing Enterobacteriaceae in Norway, 2007 to 2014. *PLoS One* 12:e0187832. <https://doi.org/10.1371/journal.pone.0187832>.
50. Schweizer C, Bischoff P, Bender J, Kola A, Gastmeier P, Hummel M, Klefisch FR, Schoenrath F, Frühauf A, Pfeifer Y. 2019. Plasmid-mediated transmission of KPC-2 carbapenemase in Enterobacteriaceae in critically ill patients. *Front Microbiol* 10:276. <https://doi.org/10.3389/fmicb.2019.00276>.
 51. Fernandes MR, Sellera FP, Moura Q, Gaspar VC, Cerdeira L, Lincopan N. 2018. International high-risk clonal lineages of CTX-M-producing *Escherichia coli* F-ST648 in free-roaming cats, South America. *Infect Genet Evol* 66:48–51. <https://doi.org/10.1016/j.meegid.2018.09.009>.
 52. Sellera FP, Fernandes MR, Moura Q, Souza TA, Cerdeira L, Lincopan N. 2017. Draft genome sequence of *Enterobacter cloacae* ST520 harbouring bla_{KPC-2}, bla_{CTX-M-15} and bla_{OXA-17} isolated from coastal waters of the South Atlantic Ocean. *J Glob Antimicrob Resist* 10:279–280. <https://doi.org/10.1016/j.jgar.2017.07.017>.
 53. Solgi H, Badmasti F, Aminzadeh Z, Giske CG, Pourahmad M, Vaziri F, Havaei SA, Shahcheraghi F. 2017. Molecular characterization of intestinal carriage of carbapenem-resistant Enterobacteriaceae among inpatients at two Iranian university hospitals: first report of co-production of bla_{NDM-7} and bla_{OXA-48}. *Eur J Clin Microbiol Infect Dis* 36:2127–2135. <https://doi.org/10.1007/s10096-017-3035-3>.
 54. Qamar MU, Walsh TR, Toleman MA, Saleem S, Jahan S. 2018. First identification of clinical isolate of a novel “NDM-4” producing *Escherichia coli* ST405 from urine sample in Pakistan. *Braz J Microbiol* 49:949–950. <https://doi.org/10.1016/j.bjm.2018.02.009>.
 55. Harada S, Suzuki M, Sasaki T, Sakurai A, Inaba M, Takuya H, Wakuda M, Doi Y. 2021. Transmission of NDM-5-producing and OXA-48-producing *Escherichia coli* sequence type 648 by international visitors without previous medical exposure. *Microbiol Spectr* 9:e01827-21. <https://doi.org/10.1128/spectrum.01827-21>.
 56. Yang RS, Feng Y, Lv XY, Duan JH, Chen J, Fang LX, Xia J, Liao XP, Sun J, Liu YH. 2016. Emergence of NDM-5- and MCR-1-producing *Escherichia coli* clones ST648 and ST156 from a single Muscovy duck (*Cairina moschata*). *Antimicrob Agents Chemother* 60:6899–6902. <https://doi.org/10.1128/AAC.01365-16>.
 57. Queenan AM, Bush K. 2007. Carbapenemases: the versatile beta-lactamases. *Clin Microbiol Rev* 20:440–458. <https://doi.org/10.1128/CMR.00001-07>.
 58. Edgell DR. 2009. Selfish DNA: homing endonucleases find a home. *Curr Biol* 19:R115–117. <https://doi.org/10.1016/j.cub.2008.12.019>.
 59. Li T, Chen H, Zhao J, Tao Z, Lan W, Zhao Y, Sun X. 2023. Characterization of phage vB_SalM_SPJ41 and the reduction of risk of antibiotic-resistant *Salmonella enterica* contamination in two ready-to-eat foods. *Antibiotics (Basel)* 12:364. <https://doi.org/10.3390/antibiotics12020364>.
 60. Nakamura G, Wachino J, Sato N, Kimura K, Yamada K, Jin W, Shibayama K, Yagi T, Kawamura K, Arakawa Y. 2014. Practical agar-based disk potentiation test for detection of fosfomycin-nonsusceptible *Escherichia coli* clinical isolates producing glutathione S-transferases. *J Clin Microbiol* 52: 3175–3179. <https://doi.org/10.1128/JCM.01094-14>.
 61. Benzerara Y, Gallah S, Hommeril B, Genel N, Decré D, Rottman M, Arlet G. 2017. Emergence of plasmid-mediated fosfomycin-resistance genes among *Escherichia coli* isolates, France. *Emerg Infect Dis* 23:1564–1567. <https://doi.org/10.3201/eid2309.170560>.
 62. Nurk S, Bankevich A, Antipov D, Gurevich AA, Korobeynikov A, Lapidus A, Pribelski AD, Pyshkin A, Sirotkin A, Sirotkin Y, Stepanauskas R, Clingenpeel SR, Woyke T, McLean JS, Lasken R, Tesler G, Alekseyev MA, Pevzner PA. 2013. Assembling single-cell genomes and mini-metagenomes from chimeric MDA products. *J Comput Biol* 20:714–737. <https://doi.org/10.1089/cmb.2013.0084>.
 63. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008. The RAST server: rapid annotations using subsystems technology. *BMC Genomics* 9:75. <https://doi.org/10.1186/1471-2164-9-75>.
 64. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother* 67:2640–2644. <https://doi.org/10.1093/jac/dks261>.
 65. Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, Huynh W, Nguyen AV, Cheng AA, Liu S, Min SY, Miroschnichenko A, Tran HK, Werfalli RE, Nasir JA, Oloni M, Speicher DJ, Florescu A, Singh B, Faltyn M, Hernandez-Koutoucheva A, Sharma AN, Bordeleau E, Pawlowski AC, Zubyk HL, Dooley D, Griffiths E, Maguire F, Winsor GL, Beiko RG, Brinkman FSL, Hsiao WWL, Domselaar GV, McArthur AG. 2020. CARD 2020: antibiotic resistance surveillance with the comprehensive antibiotic resistance database. *Nucleic Acids Res* 48:D517–D525. <https://doi.org/10.1093/nar/gkz935>.
 66. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, Møller Aarestrup F, Hasman H. 2014. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 58:3895–3903. <https://doi.org/10.1128/AAC.02412-14>.
 67. Siguier P, Perochon J, Lestrade L, Mahillon J, Chandler M. 2006. ISfinder: the reference centre for bacterial insertion sequences. *Nucleic Acids Res* 34:D32–D36. <https://doi.org/10.1093/nar/gkj014>.
 68. Larsen MV, Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, Jelsbak L, Sicheritz-Pontén T, Ussery DW, Aarestrup FM, Lund O. 2012. Multilocus sequence typing of total-genome-sequenced bacteria. *J Clin Microbiol* 50:1355–1361. <https://doi.org/10.1128/JCM.06094-11>.
 69. Sullivan MJ, Petty NK, Beatson SA. 2011. Easyfig: a genome comparison visualizer. *Bioinformatics* 27:1009–1010. <https://doi.org/10.1093/bioinformatics/btr039>.
 70. Treangen TJ, Ondov BD, Koren S, Phillippy AM. 2014. The Harvest suite for rapid core-genome alignment and visualization of thousands of intraspecific microbial genomes. *Genome Biol* 15:524. <https://doi.org/10.1186/s13059-014-0524-x>.
 71. Letunic I, Bork P. 2021. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree display and annotation. *Nucleic Acids Res* 49: W293–W296. <https://doi.org/10.1093/nar/gkab301>.
 72. Tamura K, Stecher G, Kumar S. 2021. MEGA11: Molecular Evolutionary Genetics Analysis version 11. *Mol Biol Evol* 38:3022–3027. <https://doi.org/10.1093/molbev/msab120>.
 73. Jones DT, Taylor WR, Thornton JM. 1992. The rapid generation of mutation data matrices from protein sequences. *Comput Appl Biosci* 8: 275–282. <https://doi.org/10.1093/bioinformatics/8.3.275>.
 74. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. 2005. Identification of plasmids by PCR-based replicon typing. *J Microbiol Methods* 63:219–228. <https://doi.org/10.1016/j.mimet.2005.03.018>.
 75. Sambrook J, Russell DW. 2006. Preparation and transformation of competent *E. coli* using calcium chloride. *Cold Spring Harb Protoc* 2006: pdb.prot3932. <https://doi.org/10.1101/pdb.prot3932>.
 76. Choi Y, Chan AP. 2015. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. *Bioinformatics* 31: 2745–2747. <https://doi.org/10.1093/bioinformatics/btv195>.
 77. Bitar I, Papagiannitsis CC, Kraftova L, Marchetti VM, Petinaki E, Finianos M, Chudejova K, Zemlickova H, Hrabak J. 2022. Implication of different replicons in the spread of the VIM-1-encoding integron, In110, in Enterobacteriales from Czech hospitals. *Front Microbiol* 13:993240. <https://doi.org/10.3389/fmicb.2022.993240>.